Partner Therapeutics, Inc.

Partner Therapeutics, Inc., a biopharmaceutical manufacturer based in Lexington, Massachusetts, supplies critical pharmaceutical products and medical countermeasures to federal health and defense agencies as a prime contractor, competing full-and-open without set-asides across a concentrated customer base of four federal agencies.

Partner Therapeutics operates across pharmaceutical manufacturing (NAICS 325412, 325414) and biotechnology R&D (NAICS 541711), with a prime-only footprint (100% of recent awards). The company specializes in therapeutics for sepsis, neutropenia, and other urgent medical conditions, with particular depth in sargramostim (Leukine) supply and related immunological biomarker development. The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response accounts for 96% of the vendor's combined potential value ($919.5 million across 9 awards), followed by the Department of the Army's Joint Program Executive Office Chemical and Biological Defense ($22.3 million), and the Department of Veterans Affairs Veterans Health Administration across two regional networks ($19.4 million combined). This concentration reflects Partner Therapeutics' role as a specialized medical countermeasure supplier rather than a broad-based pharmaceutical vendor.

Partner Therapeutics places most high-value work under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (5 delivery orders, $192.7 million combined potential value), supplemented by the HHS Colony Stimulating Factor vehicle (2 task orders, $51.6 million combined potential value) and direct definitive contracts. The vendor's largest single award is a $133.5 million delivery order from HHS ASPR issued in September 2023 for Leukine 250mcg vial injectables as a medical countermeasure, extending through March 29, 2027. The second-largest is a $59 million delivery order from the same agency dated July 2022 (ultimate completion March 29, 2024). Major development work includes a $13.7 million HHS ASPR definitive contract awarded September 2024 for advanced development of Leukine, mHLA-DR, and other biomarkers predictive of sepsis, running through September 2028; a $748,000 HHS ASPR contract from September 2023 for R&D to repurpose FX06 (a host-directed therapy) for Sudan Virus Disease and other filoviruses; a $748,912 definitive contract from HHS ASPR (September 2021) for diagnostic test development in sepsis and immunoparalysis; and a $22.3 million DoD Other Transaction IDV awarded January 2022 under PROJECT KICKOFF to advance FDA approval for Leukine in sulfur mustard injury treatment. Smaller orders from the Veterans Health Administration cover emergency pharmaceutical supplies ($72,563, $54,422, and $36,281 delivery orders issued between April and June 2026 for emergency business engagement medications). Awards per year ranged from one (2021, 2024) to three (2023, 2026), with activity showing discontinuous momentum. One award ($133.5 million) reaches ultimate completion within the next twenty-four months and faces recompete exposure. Service Contract Inventory data captures minimal invoiced activity ($0 across FY2022–FY2024) and indicates light FTE deployment (0.4 FTEs in FY2024 across one reporting contract), reflecting that Partner Therapeutics' federal revenue is dominated by product supply and fixed-price development contracts not fully captured in SCI's service-contract reporting threshold and methodology.